Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 36.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 612,366 shares of the biopharmaceutical company's stock after buying an additional 163,503 shares during the period. Loomis Sayles & Co. L P owned 1.07% of Agios Pharmaceuticals worth $27,208,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Caxton Associates LP boosted its position in shares of Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company's stock valued at $1,615,000 after acquiring an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares during the period. CANADA LIFE ASSURANCE Co increased its stake in shares of Agios Pharmaceuticals by 1.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company's stock valued at $911,000 after buying an additional 540 shares during the period. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth $37,000. Finally, Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth about $40,000.

Analyst Upgrades and Downgrades

AGIO has been the subject of several analyst reports. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Raymond James reiterated an "outperform" rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $52.33.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Up 2.8 %

Shares of Agios Pharmaceuticals stock traded up $1.59 during trading hours on Tuesday, reaching $59.10. 484,587 shares of the company's stock were exchanged, compared to its average volume of 697,306. The business has a fifty day moving average of $47.66 and a two-hundred day moving average of $44.86. The company has a market capitalization of $3.37 billion, a P/E ratio of 5.22 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.